Medication use evaluation: a work in progress.

L M Schrand; K A Behmer-Miller; M B Ross; A H Mutnick

Home/Archive/PubMed

PubMed · 11184046

Medication use evaluation: a work in progress.

L M Schrand·K A Behmer-Miller·M B Ross·A H Mutnick

View original source ↗Export metadata ↓

Abstract

The medication use evaluation (MUE) Program at the University of Iowa Hospitals and Clinics (UIHC) is a dynamic program that is constantly changing to meet the needs of this tertiary care institution. This article will provide an overview of the MUE process at UIHC as well as provide an example of a long-standing initiative that has evolved significantly since its inception in 1993. Examples of four other initiatives also will be provided to demonstrate the scope of this program. The examples to be covered in this article include: 5-HT3 receptor antagonists, alteplase, automatic substitution of cefotaxime, proton pump inhibitors, and COX-2 selective agents.

Explore related subjects

Ceftriaxone Cost-Benefit Analysis Cyclooxygenase Inhibitors Drug Utilization Review Hospital Bed Capacity, 500 and over Hospitals, University Humans Iowa Joint Commission on Accreditation of Healthcare Organizations Professional Staff Committees Proton Pump Inhibitors Serotonin Antagonists Tissue Plasminogen Activator Treatment Outcome Journal Article

Keep this discovery

Explore connections, maps & timelines

BibTeX RIS

L M Schrand, K A Behmer-Miller, M B Ross, A H Mutnick. 2000. Medication use evaluation: a work in progress.. https://pubmed.ncbi.nlm.nih.gov/11184046/

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed2003

Treating post Lyme disease: trying to solve one equation with too many unknowns.

Explore the source record for details and available documents.

Ceftriaxone↗

PubMed2003

Citrobacter koseri (diversus) meningitis in an otherwise healthy adolescent.

Citrobacter infection is commonly reported in neonates and immunocompromised patients. Citrobacter koseri (diversus) is an important cause of neonatal meningitis and brain abscess formation. It adults, however, Citrobacter infection with central nervous system involvement is rare, and is usually associated with an underlying disorder. This report describes a 12-y-old previously healthy girl with Citrobacter koseri meningitis. Intravenous treatment with ceftriaxone for 10 d led to complete recovery. Head computed tomography and brainstem-evoked response audiometry were normal. On follow-up, the patient was completely healthy. Previously reported cases of C. koseri meningitis in the adult population were associated with underlying predisposing factors. In this case a normal, healthy adolescent was treated with intravenous ceftriaxone without any of the known neurological complications observed in the neonatal cases.

Ceftriaxone↗

PubMed2003

HACEK endocarditis in infants and children: two cases and a literature review.

We report 2 cases of Haemophilus parainfluenzae endocarditis and review 34 cases of HACEK endocarditis from the literature. HACEK organisms are the most common cause of Gram-negative endocarditis in children. They have a propensity to form friable vegetations (especially H. parainfluenzae) that break off and cause symptomatic emboli. HACEK endocarditis (from a review of the 36 published cases) may involve previously normal hearts (33%), may be complicated by embolization (31%) and may require vegetectomy or other surgery (31%). Mortality with HACEK endocarditis was 14%. HACEK organisms may be resistant to penicillins but are susceptible to third generation cephalosporins.

Ceftriaxone↗